[go: up one dir, main page]

AR004360A1 - Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas. - Google Patents

Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas.

Info

Publication number
AR004360A1
AR004360A1 ARP960105480A ARP960105480A AR004360A1 AR 004360 A1 AR004360 A1 AR 004360A1 AR P960105480 A ARP960105480 A AR P960105480A AR P960105480 A ARP960105480 A AR P960105480A AR 004360 A1 AR004360 A1 AR 004360A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
carcinomas
therapy
agent
employed
Prior art date
Application number
ARP960105480A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Karlsruhe Forschzent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim Int, Karlsruhe Forschzent filed Critical Boehringer Ingelheim Int
Publication of AR004360A1 publication Critical patent/AR004360A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

El invento se refiere a las composiciones farmacéuticas para la terapia de carcinomas del epitelio plano, porque contienen una molécula deanticuerpo que es específica de un epítopo dentro de la secuencia de aminoácidos que escodificad a por el exón variable v6 del gen CD44. También serefiere a un agente para ser empleado en estas composiciones farmacéuticas, que es un anticuerpo o una molécula de anticuerpo que es específico de un epitopoque es codificado por el exón v6del gen CD 44.
ARP960105480A 1995-12-06 1996-12-04 Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas. AR004360A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17

Publications (1)

Publication Number Publication Date
AR004360A1 true AR004360A1 (es) 1998-11-04

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105480A AR004360A1 (es) 1995-12-06 1996-12-04 Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas.

Country Status (26)

Country Link
EP (1) EP0865609B1 (es)
JP (1) JP2000502067A (es)
KR (1) KR100473824B1 (es)
CN (1) CN1151377C (es)
AR (1) AR004360A1 (es)
AT (1) ATE235056T1 (es)
AU (1) AU726704B2 (es)
BG (1) BG62985B1 (es)
BR (1) BR9611901A (es)
CA (1) CA2239709A1 (es)
CO (1) CO4520233A1 (es)
CZ (1) CZ174198A3 (es)
DE (1) DE59610248D1 (es)
DK (1) DK0865609T3 (es)
EE (1) EE03783B1 (es)
ES (1) ES2190484T3 (es)
HK (1) HK1011560A1 (es)
MX (1) MX9804459A (es)
NO (1) NO319903B1 (es)
NZ (1) NZ324314A (es)
PL (1) PL184521B1 (es)
PT (1) PT865609E (es)
SK (1) SK284378B6 (es)
TR (1) TR199801027T2 (es)
UY (1) UY24389A1 (es)
WO (1) WO1997021104A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
PE20021098A1 (es) * 2001-05-18 2003-02-11 Boehringer Ingelheim Int ANTICUERPOS ESPECIFICOS DE CD44v6
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
RS53327B (en) * 2010-02-04 2014-10-31 University Of Miami Monoclonal antibody to CD44, for use in the treatment of squamous cell carcinoma of the head and neck
US9218450B2 (en) * 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
CN112105643B (zh) * 2018-02-22 2023-09-26 普众发现医药科技(上海)有限公司 治疗性抗体及其应用
AU2023274919A1 (en) 2022-05-25 2024-12-05 Akiram Therapeutics Ab Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678487B2 (en) * 1993-06-18 1997-05-29 Oy Biotie Therapies Ltd Compositions and diagnostic methods using monoclonal antibodies against CD44v6
US6010865A (en) * 1993-06-22 2000-01-04 Boehringer Ingelheim International Gmbh Process for detecting a variant CD44 gene product
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
BG62985B1 (bg) 2000-12-29
TR199801027T2 (xx) 1998-10-21
EP0865609A1 (de) 1998-09-23
CO4520233A1 (es) 1997-10-15
JP2000502067A (ja) 2000-02-22
MX9804459A (es) 1998-09-30
AU1177397A (en) 1997-06-27
SK73698A3 (en) 1999-01-11
PL327066A1 (en) 1998-11-23
CN1151377C (zh) 2004-05-26
AU726704B2 (en) 2000-11-16
ES2190484T3 (es) 2003-08-01
HK1011560A1 (en) 1999-07-16
CZ174198A3 (cs) 1999-02-17
BG102513A (en) 1999-02-26
EE03783B1 (et) 2002-06-17
NO982588D0 (no) 1998-06-05
EP0865609B1 (de) 2003-03-19
DK0865609T3 (da) 2003-06-23
BR9611901A (pt) 1999-03-02
KR100473824B1 (ko) 2005-09-30
WO1997021104A1 (de) 1997-06-12
CN1207811A (zh) 1999-02-10
NO982588L (no) 1998-08-05
ATE235056T1 (de) 2003-04-15
UY24389A1 (es) 2001-10-25
NZ324314A (en) 2000-02-28
SK284378B6 (sk) 2005-02-04
PL184521B1 (pl) 2002-11-29
CA2239709A1 (en) 1997-06-12
DE59610248D1 (de) 2003-04-24
NO319903B1 (no) 2005-09-26
EE9800164A (et) 1998-12-15
PT865609E (pt) 2003-08-29
KR19990071952A (ko) 1999-09-27

Similar Documents

Publication Publication Date Title
AR004360A1 (es) Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas.
BR0211390A (pt) Tratamento de infecções da unha com no
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
ECSP024352A (es) Nueva composicion farmaceutica
ATE240395T1 (de) Antikörper gegen e-selektin
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
ES2172024T3 (es) Composicion para el tratamiento del cabello que contiene un complejo de aminoacido-metal.
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
DK0705100T3 (da) Terapeutiske substituerede guanidiner
FI833605A (fi) Ny oral mopidamolprodukt
ES2130575T3 (es) Composiciones inmunogenicas mejoradas contra la gastrina 17 humana.
DE59508864D1 (de) MONOKLONALER ANTIKÖRPER GEGEN CD44v6
AR016295A1 (es) Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
BR9801736A (pt) Processo de produção de dextrano.
BR0213298A (pt) formulações com alta concentração de proteìna e processo de fabricação
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
MX169940B (es) Composiciones para el cuidado del cabello
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
ES2163634T3 (es) Benzopiranos y composiciones farmaceuticas que les contienen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure